PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E less than half of TRVN's 0.42. Charlie Munger would verify if this conservative approach provides competitive advantages.
2.11
Net debt 50-75% of TRVN's 2.41. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
-36.71
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
2.36
Current ratio 50-75% of TRVN's 3.55. Bill Ackman would demand clear path to liquidity improvement.
No Data
No Data available this quarter, please select a different quarter.